Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring

Wenhui Jia, Yuanzhe Wu, Qin Zhang, Ge Gao, Chen‐Yu Zhang, Yang XiangMolecular 2015 · DOI

Abstract

Sensitive and specific biomarkers for the early detection of cervical cancer are urgently required to reduce the high morbidity and mortality of this disease. We previously demonstrated that circulating microRNAs (miRNAs) are correlated with certain types of human cancer. The aim of this study was to investigate the altered profile of serum miRNAs in cervical cancer patients in order to predict cervical cancer at a relative early stage. Serum samples were collected from 213 cervical cancer patients and 158 age- and ethnicity-matched controls. An initial screening of miRNA expression was performed by Solexa sequencing. Differential expression was validated using the stem-loop miRNA quantitative polymerase chain reaction (qPCR) assay in individual samples and the samples were arranged by two-phase selection and validation. The Solexa sequencing results revealed 12 markedly upregulated serum miRNAs in cervical cancer patients compared with controls. The reverse transcription-qPCR analysis identified a profile of 5 serum miRNAs (miR-21, -29a, -25, -200a and -486-5p) as a cervical cancer biomarker. The receiver operating characteristic curves indicated that a panel of 5 miRNAs constitutes a more sensitive and specific diagnostic test compared with any single miRNA-based assay, the squamous cell carcinoma antigen or the carbohydrate antigen 125. More importantly, miR-29a and miR-200a may indicate tumor histological grade and progression stage. Therefore, a 5-miRNA signature identified from genome-wide serum miRNA expression profiling may serve as a fingerprint for cervical cancer diagnosis.

Introduction

Cervical cancer remains a leading cause of mortality among women globally, largely because early stages are often asymptomatic. While the Papanicolaou (Pap) smear is a standard screening tool, its sensitivity can be as low as 51%, and it is less effective at detecting certain types of adenocarcinoma. Other diagnostic methods, like colposcopy and biopsies, are invasive. Current blood-based biomarkers, such as the squamous cell carcinoma (SCC) antigen and carbohydrate antigen 125 (CA125), suffer from poor sensitivity and specificity, making them unreliable for early detection. There is a critical need for a stable, non-invasive, and highly accurate biomarker that can catch cervical cancer before it progresses to an invasive stage.

Methods

The study employed a multi-stage "funnel" approach to narrow down thousands of potential candidates to a robust diagnostic panel.

Overview of the multi-phase study design for biomarker discovery and validation.
  1. Initial Screening: Solexa sequencing was used on pooled serum samples from 90 patients and 64 controls to identify significantly upregulated miRNAs.
  2. Selection Phase: Using RT-qPCR, the top candidates were tested on a "training set" of 20 patients and 20 controls.
  3. Validation Phase: The resulting 5-miRNA signature was rigorously tested on a larger, independent "validation set" (103 patients and 74 controls).
  4. Statistical Modeling: A Risk Score Function (RSF) combined the expression levels of the five miRNAs into a single diagnostic score. Receiver Operating Characteristic (ROC) curves evaluated the diagnostic power (Area Under the Curve, or AUC) of the panel.

Because there is no universal "housekeeping" gene for serum miRNA, the authors used a stable mixture of three let-7 family miRNAs (let-7i, -7g, and -7d) as a reference control.

Results and Key Insights

The study identified a profile of five serum miRNAs—miR-21, miR-29a, miR-25, miR-200a, and miR-486-5p—that were significantly elevated in cervical cancer patients compared to healthy controls.

Relative fold change of the five selected serum miRNAs in cervical cancer patients versus healthy controls.

Diagnostic Performance

The 5-miRNA panel demonstrated superior diagnostic performance:

  • Overall Accuracy: The panel achieved an AUC of 0.908.
  • Sensitivity and Specificity: At the optimal cutoff, the test showed 81.0% sensitivity and 88.6% specificity.
  • Comparison to Standard Markers: The miRNA panel vastly outperformed traditional markers. For the same patient group, the SCC antigen had an AUC of only 0.655, and CA125 had an AUC of 0.570.
  • Early Detection: The signature was significantly elevated even in patients with Cervical Intraepithelial Neoplasia (CIN), suggesting potential for very early intervention.

Clinical Correlation

Two specific miRNAs—miR-29a and miR-200a—showed a progressive increase in expression as tumor grade became poorer and the stage became more advanced, suggesting utility in monitoring disease progression.

Discussion and Limitations

While the 5-miRNA signature is a promising "molecular fingerprint" for cervical cancer, several areas require further exploration. The study was conducted on a specific population in China; larger, multi-center international trials are needed to ensure universal applicability. Additionally, the sample size for advanced stages (III and IV) was relatively small. Future research should investigate the biological pathways these miRNAs regulate, particularly their interaction with HPV oncogenes, and evaluate the panel's effectiveness in tracking real-time response to therapy.

Summary updated

Abstract

Sensitive and specific biomarkers for the early detection of cervical cancer are urgently required to reduce the high morbidity and mortality of this disease. We previously demonstrated that circulating microRNAs (miRNAs) are correlated with certain types of human cancer. The aim of this study was to investigate the altered profile of serum miRNAs in cervical cancer patients in order to predict cervical cancer at a relative early stage. Serum samples were collected from 213 cervical cancer patients and 158 age- and ethnicity-matched controls. An initial screening of miRNA expression was performed by Solexa sequencing. Differential expression was validated using the stem-loop miRNA quantitative polymerase chain reaction (qPCR) assay in individual samples and the samples were arranged by two-phase selection and validation. The Solexa sequencing results revealed 12 markedly upregulated serum miRNAs in cervical cancer patients compared with controls. The reverse transcription-qPCR analysis identified a profile of 5 serum miRNAs (miR-21, -29a, -25, -200a and -486-5p) as a cervical cancer biomarker. The receiver operating characteristic curves indicated that a panel of 5 miRNAs constitutes a more sensitive and specific diagnostic test compared with any single miRNA-based assay, the squamous cell carcinoma antigen or the carbohydrate antigen 125. More importantly, miR-29a and miR-200a may indicate tumor histological grade and progression stage. Therefore, a 5-miRNA signature identified from genome-wide serum miRNA expression profiling may serve as a fingerprint for cervical cancer diagnosis.
BibTeX
@inproceedings{jia2015expression,
  author = {Wenhui Jia and Yuanzhe Wu and Qin Zhang and Ge Gao and Chen‐Yu Zhang and Yang Xiang},
  title = {{Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring}},
  booktitle = {Molecular},
  year = {2015},
  doi = {10.3892/mco.2015.560},
}
Figure